DNA
Ginkgo Bioworks Holdings, Inc.Company Information
- Company Name
- Ginkgo Bioworks Holdings, Inc.
- CIK
- CIK0001830214
- Category
- Accelerated filer
- Ticker: Exchange
- DNA: NYSE, DNABW: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- DNA
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-05-15
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 434,674
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 35,783,686
- Shares outstanding
- 62,094,356
- Ownership
- 57.63%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -18.12%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 85 | 144 | 167 | 111 | 204 | 312 | 562 | 616 | 730 | 840 | 944 | 1,049 | ||||||
| Marketable Securities Current | - | - | 255 | - | - | - | 0 | - | - | - | - | - | ||||||
| Marketable Securities | 218 | 230 | - | 351 | 270 | 205 | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 333 | 410 | 472 | 506 | 523 | 565 | 603 | 662 | 783 | 903 | 1,002 | 1,142 | ||||||
| Accounts Receivable Net Current | 13 | 20 | 24 | 21 | 22 | 26 | 22 | 23 | 19 | 24 | 17 | 62 | ||||||
| Accounts Receivable Net | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | ||||||
| Inventory Net | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 17 | 16 | 25 | 22 | 26 | 20 | 19 | 22 | 34 | 38 | 40 | 29 | ||||||
| Restricted Cash Noncurrent | 85 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 157 | 163 | 168 | 177 | 186 | 198 | 204 | 211 | 211 | 196 | 188 | 202 | ||||||
| Operating Lease Right Of Use Asset | 348 | 354 | 361 | 368 | 376 | 383 | 394 | 406 | 418 | 221 | 207 | 342 | ||||||
| Equity Securities Fv Ni And Without Readily Determinable Fair Value | 15 | 15 | 15 | 30 | 33 | 32 | 49 | 62 | 62 | 76 | 79 | 85 | ||||||
| Equity Method Investments | 8 | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 44 | 49 | 57 | 62 | 66 | 69 | 73 | 80 | 91 | 77 | 83 | 100 | ||||||
| Goodwill | - | - | - | - | - | - | 0 | 0 | 0 | 48 | 49 | 58 | ||||||
| Other Assets Noncurrent | 1 | 40 | 47 | 47 | 47 | 47 | 55 | 60 | 60 | 61 | 58 | 97 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | 0 | 3 | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 990 | 1,033 | 1,120 | 1,189 | 1,231 | 1,293 | 1,377 | 1,481 | 1,625 | 1,582 | 1,665 | 2,026 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 10 | 16 | 11 | 11 | 11 | 11 | 14 | 16 | 23 | 27 | 9 | 11 | ||||||
Liabilities Current | ||||||||||||||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | - | - | - | - | 43 | ||||||
| Liabilities Current | 73 | 80 | 96 | 115 | 97 | 116 | 107 | 114 | 166 | 169 | 164 | 168 | ||||||
| Contract With Customer Liability Current | 13 | 15 | 19 | 25 | 28 | 34 | 28 | 23 | 26 | 34 | 44 | - | ||||||
| Accrued Liabilities And Other Liabilities | 50 | 48 | 66 | 79 | 57 | 71 | 65 | 76 | 117 | 108 | 110 | 115 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 170 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | 77 | 78 | 75 | 74 | 75 | 80 | 99 | 105 | 153 | 166 | 158 | - | ||||||
| Operating Lease Liability Noncurrent | 404 | 411 | 417 | 423 | 429 | 435 | 439 | 446 | 452 | 234 | 222 | 404 | ||||||
| Other Liabilities Noncurrent | 16 | 22 | 23 | 17 | 18 | 15 | 17 | 18 | 21 | 25 | 24 | 19 | ||||||
| Warrants And Rights Outstanding | - | - | - | - | - | - | - | - | - | - | 6 | 12 | ||||||
| Liabilities | 570 | 590 | 611 | 629 | 618 | 646 | 661 | 683 | 792 | 594 | 568 | 774 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 6,699 | 6,675 | 6,657 | 6,627 | 6,600 | 6,577 | 6,555 | 6,528 | 6,508 | 6,445 | 6,386 | 6,334 | ||||||
| Stockholders Equity | 420 | 443 | 509 | 560 | 613 | 647 | 716 | 798 | 833 | 987 | 1,097 | 1,253 | ||||||
| Retained Earnings Accumulated Deficit | -6,280 | -6,233 | -6,150 | -6,070 | -5,989 | -5,929 | -5,838 | -5,730 | -5,674 | -5,456 | -5,291 | -5,079 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 2 | 2 | 2 | -1 | -2 | 0 | -2 | -2 | 1 | -3 | ||||||
| Liabilities And Stockholders Equity | 990 | 1,033 | 1,120 | 1,189 | 1,231 | 1,293 | 1,377 | 1,481 | 1,625 | 1,582 | 1,665 | 2,026 | ||||||
| Related Party | 4 | 0 | 0 | 0 | -0 | 0 | 1 | -1 | 1 | 1 | 5 | -1 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Revenues | - | - | - | - | - | - | - | - | - | - | - | 55 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGinkgo Bioworks Holdings, Inc. (DNA) — SEC Financial Statements & Analysis
Ginkgo Bioworks Holdings, Inc. (DNA) is a biological products, (no diagnostic substances) company, incorporated in DE. Ginkgo Bioworks Holdings, Inc. trades on NYSE, OTC as: DNA, DNABW. Ginkgo Bioworks Holdings, Inc. (DNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Ginkgo Bioworks Holdings, Inc. carries a market cap of $615.36M, a P/E ratio of -2.12x, a P/B ratio of 1.46x, a P/S ratio of 4.65x, an enterprise value of $443.34M, and an EV/EBITDA multiple of -1.77x. On profitability, it posts a gross margin of 79.71%, an operating margin of -231.13%, a net margin of -219.60%, a Return on Equity (ROE) of -56.29%, a Return on Assets (ROA) of -26.19%, and a Return on Invested Capital (ROIC) of -91.94%. Per share, it reports EPS of $-4.68, diluted EPS of $-5.64, free cash flow per share of $-2.82, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -37.02% year-over-year, net income growth of -7.74% year-over-year, and EPS growth of -18.49% year-over-year. On the balance sheet, it maintains a current ratio of 4.57x, a quick ratio of 4.33x, working capital of $259.80M, a debt-to-equity ratio of 1.36x, a debt ratio of 0.58, an interest coverage ratio of -24.35x, free cash flow of $-174.80M (TTM), and net debt of $-172.01M. Figures sourced from SEC EDGAR.
- Market Cap
- $615.36M
- P/E TTM
- -2.12x
- EPS TTM
- $-4.68
- P/B TTM
- 1.46x
- ROE TTM
- -56.29%
- ROA TTM
- -26.19%
- Debt To Equity
- 1.36x
- Free Cash Flow TTM
- $-174.80M
- Net Revenue TTM Growth 1Y
- -37.02%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Ginkgo Bioworks Holdings, Inc. in?
Ginkgo Bioworks Holdings, Inc. (DNA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does DNA trade on?
Ginkgo Bioworks Holdings, Inc. (DNA) trades on the NYSE, OTC.
Where is Ginkgo Bioworks Holdings, Inc. incorporated?
Ginkgo Bioworks Holdings, Inc. is incorporated in DE.
When was Ginkgo Bioworks Holdings, Inc. (DNA)'s most recent SEC filing?
Ginkgo Bioworks Holdings, Inc. (DNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is DNA's market cap?
Ginkgo Bioworks Holdings, Inc. (DNA) has a market capitalization of $615.36M as of 2026-06-30.
What is DNA's EPS (earnings per share)?
Ginkgo Bioworks Holdings, Inc. (DNA)'s trailing twelve month EPS is $-4.68 as of 2026-06-30.
What is DNA's ROE (return on equity)?
Ginkgo Bioworks Holdings, Inc. (DNA)'s trailing twelve month Return on Equity (ROE) is -56.29% as of 2026-06-30.
What is DNA's ROA (return on assets)?
Ginkgo Bioworks Holdings, Inc. (DNA)'s trailing twelve month Return on Assets (ROA) is -26.19% as of 2026-06-30.
What is DNA's ROIC (return on invested capital)?
Ginkgo Bioworks Holdings, Inc. (DNA)'s trailing twelve month Return on Invested Capital (ROIC) is -91.94% as of 2026-06-30.
What is DNA's EV/EBITDA?
Ginkgo Bioworks Holdings, Inc. (DNA)'s trailing twelve month EV/EBITDA is -1.77x as of 2026-06-30.